Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07203287 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Risk of Acute Complications With Rocuronium vs Cisatracurium in Patients With Chronic Kidney Disease

StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

  1. Site contact updatedv3
  2. Primary completion date: Sep 26, 2025 to Dec 31, 2026
    • Interventions: Cisatracurium (Drug), Rocuronium (Drug) to Cisatracurium (Drug), Neostigmine (Drug), Rocuronium (Drug), Sugammadex (Drug)
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of the study is to determine which combination of neuromuscular blocking agent and reversal agent is safer to use during anesthesia for patients with chronic kidney disease. The main question it aims to answer is "The use of Cisatracurium with neostigmine leads to less post-operative pulmonary complications than Rocuronium with sugammadex."
Trial Details
NCT Number NCT07203287
Lead Sponsor The University of Texas Medical Branch, Galveston
Conditions
(from sponsor)		 Post Operative Pulmonary Complications, Neuromuscular Blockade, General Anesthesia
Enrollment 490 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov